Larry Norton Selected Research

Adjuvant Chemotherapy

05/2008	Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
08/2007	Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
07/2005	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
04/2005	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
03/2005	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
01/2005	Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
01/2005	Dose-dense adjuvant chemotherapy for primary breast cancer.
01/2005	Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
08/2003	Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.
05/2003	Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
03/2003	Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Articles by Research Topic

Disease

45	Breast Neoplasms (Breast Cancer) 05/2008 - 02/2002
15	Neoplasms (Cancer) 05/2008 - 02/2002
9	Leukemia 05/2008 - 02/2002
3	Carcinoma (Carcinomatosis) 10/2005 - 05/2003
1	Amenorrhea 10/2005
1	Radiation Pneumonitis (Radiation Fibrosis) 09/2005

Drug/Important Bio-Agent (IBA)

11	Paclitaxel (Taxol)FDA LinkGeneric 05/2008 - 09/2002
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2008 - 02/2002
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2008 - 02/2002
4	Tamoxifen FDA LinkGeneric 04/2008 - 11/2003
4	letrozole (Femara)FDA Link 04/2008 - 11/2003
4	trastuzumab (Herceptin)FDA Link 04/2008 - 06/2004
4	taxaneIBA 10/2005 - 05/2002
3	Fluorouracil (Carac)FDA LinkGeneric 05/2008 - 02/2002
2	Filgrastim (Neupogen)FDA Link 05/2008 - 01/2007
2	Estrogens (Estrogen)FDA Link 05/2007 - 04/2006
2	TaxoidsIBA 09/2005 - 09/2004
1	capecitabine (Xeloda)FDA Link 04/2008
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2008
1	Phosphotransferases (Kinase)IBA 01/2008
1	Biological Tumor Markers (Tumor Markers)IBA 11/2007
1	flt3 ligand protein (flt3 ligand)IBA 10/2007
1	DNA (Deoxyribonucleic Acid)IBA 10/2007
1	Progesterone Receptors (Progesterone Receptor)IBA 05/2007
1	QS 21 (QS21)IBA 05/2007
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 05/2007
1	sialyl-Tn antigen-keyhole-limpet hemocyanin conjugateIBA 05/2007
1	Dihydrotachysterol (AT 10)IBA 01/2007
1	Epirubicin (Ellence)FDA LinkGeneric 01/2007
1	Interleukin-6 (Interleukin 6)IBA 12/2006
1	bevacizumab FDA Link 11/2006
1	cetuximab (Erbitux)FDA Link 08/2006
1	gemcitabine FDA Link 04/2005
1	imatinib (Gleevec)FDA Link 03/2005
1	docetaxel (Taxotere)FDA Link 01/2005
1	CreatinineIBA 01/2005
1	Keratins (Keratin)IBA 09/2004
1	celecoxib (Celebrex)FDA Link 06/2004
1	Methotrexate (Mexate)FDA LinkGeneric 05/2003
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2002
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2002

Therapy/Procedure

11	Adjuvant Chemotherapy 05/2008 - 03/2003
7	Drug Therapy (Chemotherapy) 08/2006 - 02/2002
1	Ovariectomy (Oophorectomy) 03/2008
1	Segmental Mastectomy (Lumpectomy) 09/2004
1	Mastectomy (Mammectomy) 09/2004
1	Combination Drug Therapy (Combination Chemotherapy) 04/2003
1	Transplants (Transplant) 02/2002